Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients- A Case Series

Southern California University of Health Sciences1 site in 1 country10 target enrollmentOctober 2015

ConditionsSensation Disorders Neuropathy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sensation Disorders
Sponsor: Southern California University of Health Sciences
Enrollment: 10
Locations: 1
Primary Endpoint: Changes in perceived neuropathy as measured by EORTC CIPN-20
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this study is to collect preliminary data on the effectiveness of acupuncture for the treatment of CIPN in breast cancer patients.

Detailed Description

Ideally 10 patients experiencing peripheral neuropathy due to chemotherapy from breast cancer treatment will be included in this study.They will receive 16 total acupuncture treatments over 10 weeks including various points based off of research and classical text and scalp acupuncture.

Registry

clinicaltrials.gov

Start Date

October 2015

End Date

December 2018

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Female

Investigators

Sponsor

Southern California University of Health Sciences

Responsible Party

Principal Investigator

Sivarama Vinjamury

Professor

Southern California University of Health Sciences

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Receiving any treatment to prevent neuropathy 2 weeks prior to the screening
•Pre-existing peripheral neuropathy due to any other cause than chemotherapy
•Pre-existing conditions like pregnancy, uncontrolled diabetes, hypertension, cardiovascular disorders, bleeding disorders, depression (BDI \> 21)
•Unwilling to follow the protocol
•Individuals who are receiving government disability assistance

Outcomes

Primary Outcomes

Changes in perceived neuropathy as measured by EORTC CIPN-20

Time Frame: At baseline, week 6 (treatment 12) and at week 10 (treatment 16)

This is a 20-item self-report multidimensional CIPN specific scale that measures sensory, motor and autonomic symptoms of a 1-4 Likert scale.

Secondary Outcomes

Changes in quality of life as measured by EORTC QLQ-30(At baseline, week 6 (treatment 12) and at week 10 (treatment 16))
Changes in perceived neuropathy as measured by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG) Questionnaire(At baseline, week 6 (treatment 12) and at week 10 (treatment 16))
Changes in perceived neuropathy as measured by Visual Analogue Scale of Pain(At baseline, week 6 (treatment 12) and at week 10 (treatment 16))